PHSI-BRG
PHSI-BRG
Home
Staff
Sarah Al Ashmori
Andy Bryant
Thomas Chadwick
Svetlana Cherlin
Mike Cole
Holly Fisher
Tony Fouweather
Shaun Hiu
Dorcas Kareithi
Ann Breeze Konkoth
Nan Lin
Jingky Lozano-Kuehne
Helen Mossop
Ellen Moss
Aritra Mukherjee
Jérémie Nsengimana
Vicky Ryan
Marzieh Shahmandi
Moha Shojaei
Dawn Teare
James Wason
Faye Williamson
Nina Wilson
Sylvia Zhang
PhD students
Ruqayya Azher
Nicole Cizauskas
Laura Etfer
Niamh Fitzgerald
Raiann Hamshaw
Pela Okorie
Samuel Sarkodie
Lou Whitehead
Methodology research
Overview
Adaptive designs
Master protocols
Transforming IMID trials
Projects
Publications
News
Courses
Adaptive Designs and Multiple Testing Procedures
Leveraging External Information
Precision Medicine Clinical Trials
Contact
Light
Dark
Automatic
Boddy AV
Latest
Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma
Abstract 4651: Characterization of the clinical pharmacokinetics of actinomycin D and the influence of pharmacogenetic variation in children with cancer
Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer
Population pharmacokinetic investigation of actinomycin-D in children and young adults
Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma
Pharmacokinetics of high-dose cyclophosphamide and its metabolites in paediatric patients
Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy
Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide
Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients
Estimation of renal function and its potential impact on carboplatin dosing in children with cancer
Estimation of renal function and its potential impact on carboplatin dosing in children with cancer
Pharmacogenetic influences on outcome from AC chemotherapy in the treatment of breast cancer
Pharmacogenetics and metabolism of cyclophosphamidein paediatric cancer patients
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – A study of the United Kingdom Children's Cancer Study Group
Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma – A study of the United Kingdom Children′s Cancer Study Group
Potential clinical impact of taking multiple blood samples for research studies in paediatric oncology: How much do we really know?
A study to determine the minimum volume of blood necessary to be discarded from a central venous catheter before a valid sample is obtained in children with cancer
Pharmacokinetics of dactinomycin in a pediatric patient population: A United Kingdom Children's Cancer Study Group Study
Estimation of glomerular filtration rate in paediatric cancer patients using 51CR-EDTA population pharmacokinetics
Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide
Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion
Cyclophosphamide metabolism in children with Fanconi's anaemia
Cyclophosphamide metabolism in children with Fanconi's anaemia
The effect of fluconazole on cyclophosphamide metabolism in children
Cyclophosphamide pharmacokinetics in children
Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients
The kinetics of the auto-induction of ifosfamide metabolism during continuous infusion
Cite
×